Purchase Order 75N95019P00612
Award Date 9/9/19
Potential Completion Date 4/30/20
Potential Value $109K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Reaction Biology Corporation was awarded a $16,480.80 firm fixed price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to test 35 novel small molecule compounds for inhibition of three wild-type kinase enzymes. Under the contract, Reaction Biology will utilize its Kinase HotSpot assay platform to test each compound at 10 different doses and provide one comprehensive report detailing results against the three kinases. The testing services...
- This federal contract award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), was issued to Reaction Biology Corporation, a self-certified small disadvantaged business based in Malvern, PA. The $150,330 firm-fixed-price purchase order contract requires Reaction Biology to provide compound testing services, including screening 10 small molecule compounds against a panel of 50 kinases and 5 compounds against a panel of 374 kinases using the Kinase...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Reaction Biology Corporation, a small disadvantaged business contractor. The contract is for the testing of compounds for inhibition of 370 wild-type kinase enzymes, with a potential value of $166,500.00 and a completion date of December 6, 2022. Reaction Biology has previously provided kinase inhibition testing, cancer cell line...
- Reaction Biology Corporation has been awarded a $100,560 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to provide GAMMA 33P ATP Kinase Assay and NanoBRET Kinase Assay testing services. As a prime contractor, Reaction Biology will utilize its Kinase HotSpot and Methyltransferase HotSpot platforms to test libraries of novel compounds against panels of wild-type kinases and...
- The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $110,000.00 firm fixed price purchase order to Reaction Biology Corporation, a self-certified small disadvantaged business, for the testing of compounds to inhibit wild-type kinase enzymes. This requirement does not have a set-aside designation. Reaction Biology Corporation is a contract research organization that provides specialized bioassay testing and...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...
- This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The $102,100 contract is for testing 10 novel small molecule compounds against a panel of 50 wild-type kinases, as well as testing 5 compounds against a more comprehensive panel of 374 wild-type kinases. The purpose is to assess the kinase...
- This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
- This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...